

January, 2022

Yi Jin

CURRICULUM VITAE



Name: Yi Jin, M.D.
Telephone: (949) 899-7993 (cell)
Email: jinyi@twc.com

SUMMARY

Yi Jin, MD, was a medical school graduate and practiced as a clinical psychiatrist until 1986. In the past 38 years, Dr. Jin has been focused primarily on teaching and research at the UCLA, UC Irvine, UCSD, and USC. His main academic interests have been to find out the neuro-physical process in normal and abnormal cognition. Using various types of sensory stimulations and neural imaging recording, he has found that the brain cognitive process is discrete and its accuracy depends on the internal rhythmic oscillation. The rhythmicity itself, however, is “tunable” via proper external stimulation. This discovery opens up a new avenue for treatment of mental disorders. During the past 24 years, he has studied a novel physical treatment, repetitive transcranial magnetic stimulation (TMS). Using individual’s brain wave frequencies and their variations as well as other measures of biological matrix, he has successfully treated many patients with various types of neuropsychiatric disorders, including schizophrenia, major depression, anxiety, substance abuse, and autism. Several results have been published in peer-reviewed journals or presented on academic conferences. In addition to the academic works at the Universities, Dr. Jin has also cofounded two companies, NeoSync, Inc. and Brain Treatment Center (BTC) since 2007. NeoSync is a privately funded corporation manufacturing portable TMS instruments, and BTC, a psychiatric clinic using EEG and TMS to assist clinical diagnosis and treatment for autistic spectral disorder (ASD) and other mental disorders.

EDUCATION

Fellowship

Sept. 1987 - Aug. 1988:	Postdoctoral Fellow Department of Psychiatry and Human Behavior UCI Medical Center
Aug. 1986 - Aug. 1987:	Visiting Fellow in Consultation-Liaison Psychiatry Neuropsychiatric Institute UCLA School of Medicine
Jun. 1987 - Aug. 1987:	Postdoctoral Fellow Reise-David Child Center Los Angeles

Residency

Sept. 1983 - Aug. 1986:	Resident Department of Psychiatry Shanghai Medical University, PRC
-------------------------	--

January, 2022

Yi Jin

Shanghai Mental Hospital / WHO Collaborating
Center for Research and Training

Medical School

Sept. 1978 - Aug. 1983: M. D.
Shanghai First Medical College
Shanghai, PRC

Languages: Chinese and English

APPOINTMENTS:

August 2020 – Present: Consultant
Brain Health Leadership Foundation

June 2019 – Present: Faculty
University of Southern California
Center for Neural Restoration
Department of Neurological Surgery

November 2009 – June 2019: Neuroscience Director / Founder
Brain Treatment Center
Newport Beach, CA

Nov. 2007 – Jan. 2011: Chief Medical Officer / Founder
NeoSync, Inc.
Newport Beach, CA

July 2008 – Present: Clinical Professor
Department of Psychiatry and Human Behavior
California College of Medicine
University of California, Irvine

Apr. 2007 – July 2009: Director of Neuroscience Center
Brookside Institute
Newport Beach, CA

July 1997 – July 2008: Associate Professor
Department of Psychiatry and Human Behavior
California College of Medicine
University of California, Irvine

July 1991 - July 1997: Assistant Professor
Department of Psychiatry and Human Behavior
California College of Medicine
University of California, Irvine

Aug. 1988 - June 1991: Staff Research Associate II
Department of Psychiatry and Human Behavior
California College of Medicine
University of California, Irvine

PUBLICATIONS

Patents

20090082690 - Systems and Methods for Neuro-EEG Synchronization Therapy

20090083071 - Systems and Methods for Controlling and Billing Neuro-EEG Synchronization Therapy

20090198144 - Systems and Methods for Anxiety Treatment Using Neuro-EEG Synchronization Therapy

20090204015 -Systems and Methods for Depression Treatment Using Neuro-EEG Synchronization Therapy

20110034822 - SYSTEMS AND METHODS FOR MODULATING THE ELECTRICAL ACTIVITY OF A BRAIN USING NEURO-EEG SYNCHRONIZATION THERAPY

20110112427 - SYSTEMS AND METHODS FOR NEURO-EEG SYNCHRONIZATION THERAPY

Books

1. Glycine in the treatment of schizophrenia: theory and preliminary results. In H.Y. Meltzer (ed) New Research Directions in the Development of Atypical and Other Novel Antipsychotic Medications. Potkin, S.G., Costa, J., Roy, S., Sramek, J., Jin, Y., Gulasekaram, B. New York: Raven Press, 1992.
2. Phenomenon of consciousness and thermodynamics (in Chinese). Peking University Press, 2011.

Journal Articles Peer Reviewed

1. An introduction to a new drug: Xanax (in Chinese). Y. Jin, Journal of Shanghai First Medical College, September, 1985
2. Effect of smoking on the patients with neuroleptics (in Chinese). L. Zhang, Y. Jin. Journal of Psychiatry and Neurology, July, 1985
3. EEG alpha photic driving abnormalities in chronic schizophrenia. D. Rice, S. Potkin, Y. Jin, et al. Psychiatry Research, 30:313-324, 1989
4. Abnormal EEG responses to photic stimulation in schizophrenic patients. Y. Jin, S. Potkin, D. Rice, et al. Schizophrenia Bulletin, 16:627-634, 1990
5. Tiospirone in Chronic Treatment-Resistant Schizophrenics. J. Sramek, J. Costa, Y. Jin, B. Gulasekaram, E. Khaled, S. Potkin and N. Cutler. Drug Investigation 2(1): 65-66, 1990
6. Measuring the psychological contract of control: Discriminant, Divergent, and Incremental Validity of Shapiro Control Inventory and Rotter's and Wallstons' Locus of Control Scales. D. Shapiro, S. Potkin, Y. Jin, J. Wu, B. Brown, D. Carreon. International Journal of Psychosomatics, 40 (1-4): 35-46, 1993.
7. Clozapine effects on glucose metabolic rate in striatum and frontal cortex. Potkin, S.G., Buchsbaum, M.S., Jin, Y., et al. J Clin Psychaitry, 55:63-66, 1994.
8. Plasma Clozapine Concentrations Predict Clinical Response in Treatment-Resistant Schizophrenia. S. Potkin, R. Bera, B. Gulasekaram, J. Costa, S. Hayes, Y. Jin, G. Richmand, D. Carreon, et al. J Clin Psychiatry 55:133-136, 1994
9. Clozapine increase EEG photic driving in clinical responders. Y. Jin, S. Potkin, C. Sandman. Schizophrenia Bulletin 21(2): 263-268, 1995
10. Topographic Analysis of EEG Photic Driving in Normal and Schizophrenic Subjects. Y. Jin, C. Sandman, J. Wu, S.G. Potkin, et al. Clinical Electroencephalography. 26(2): 102-107, 1995
11. Gender differences in the gating of the auditory evoked potential in normal subjects. W. Hetrick, C. Sandman, W. Bunney, Y. Jin, M. White. Biological Psychiatry. 39:51-58, 1996.
12. Dreams and alpha power: language in dreaming and regional EEG alpha power. Hong C, Jin Y, Potkin SG, Buchsbaum MS, et al. Sleep. 19:232-235, 1996.
13. P50 changes with visual interference in normal subjects: a sensory distraction model for schizophrenia. Jin Y, Potkin SG. Clinical EEG. 27: 151-154, 1996.
14. EEG photic driving in patients with schizophrenia and depression. Jin Y, Potkin SG, Sandman CA, Bunney WE. Biological Psychiatry 41: 46-49, 1996.
15. Effects of P50 temporal variability on sensory gating in schizophrenia. Jin Y, Potkin SG, Patterson JV, Sandman CA, Hetrick WP, Bunney WE, Jr. Psychiatry Research. 70: 71-81, 1997.

16. Topographic analysis of EEG photic driving in patients with schizophrenia following clozapine treatment. Jin Y, Potkin SG, Sandman CA, and Bunney WE, Jr. *Clinical EEG*. 29:73-78, 1998.
17. Is P50 a measure of sensory gating in schizophrenia? Jin Y, Bunney WE, Jr., Sandman C, Hetrick WP, Patterson JV, Potkin SG. *Biological Psychiatry*, 43:873-878, 1998.
18. Effect of clozapine and adjunctive high dose glycine in treatment-resistant schizophrenia. Potkin SG, Jin Y, Bunney BG, Costa J and Gulasekaram B. *Am. J. Psychiatry*, 156: 145-147, 1998.
19. A Structured Interview for Assessing Perceptual Anomalies: SIAPA. Bunney WE, Jr., Hetrick W, Garland-Bunney B, Patterson J, Jin Y, Potkin SG, Sandman C. *Schizophrenia Bulletin*, 25: 577-592, 1999.
20. Effects of temporal variability on p50 and the gating ratio in schizophrenia: a frequency domain adaptive filter single-trial analysis. Patterson, JV; Jin, Y; Gierczak, M; Hetrick, WP; Potkin, S; Bunney, WE Jr; Sandman, CA. *Archives of General Psychiatry*, 57: 57-64, 2000
21. Relative sparing of emotionally influenced memory in Alzheimer's disease. Moayeri SE; Cahill L; Jin Y; Potkin SG, *Neuro Report*, 11: 653-655, 2000
22. EEG resonant responses in schizophrenia: a photic driving study with improved harmonic resolution. Jin Y, Castellanos A, Jr., Solis ER, Jr., Potkin SG. *Schizophrenia Research*, 44: 213-220, 2000
23. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. Potkin SG, Fleming K, Jin Y, Gulasekaram B. *J Clin Psychopharmacol*. Oct; 21(5):479-83, 2001
24. Identification of diagnostic evoked response potential segments in Alzheimer's disease. Benvenuto J, Jin Y, Casale M, Lynch G, Granger R. *Exp Neurol*. 176(2):269, 2002
25. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Potkin SG, Alva G, Fleming K, Anand R, Keator D, Carreon D, Doo M, Jin Y, Wu JC, Fallon JH. *Am J Psychiatry*. 159(2):227- 37, 2002
26. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, Wu JC, Alva G, Carreon DT, Bunney WE Jr, Fallon JH, Kennedy JL. *Mol Psychiatry*.8:109-13, 2003
27. Alpha EEG predicts visual reaction times. Jin Y, James P, O'Halloran, Lawrence Plon, Curt Sandman, Steven G. Potkin. *Int. J. Neuroscience*; 116: 1-10, 2006.
28. Alpha EEG-guided rTMS in the treatment for schizophrenia. Yi Jin, Steven G. Potkin, Aaron Kemp, Steven Huerta, William E. Bunney, Jr. *Schiz. Bull.* 32: 556-561, 2006.
29. Double-blind control trial of alpha electroencephalogram-guided transcranial magnetic stimulation treatment for schizophrenia. Xu WJ, Jin Y, Huang YQ, Liu ZR, He H, and Chen J. *Chin J Clin Rehab*. 10:22-24, 2006.
30. P50 sensory gating ratios in schizophrenics and controls: A review and data analysis. Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H, Potkin S, Bunney WE Jr. *Psychiatry Res*. 158:226-47, 2008.
31. Case Study: A Forty-five Year Follow-Up EEG Study of Qigong Practice. Qin Z, Jin Y, Lin S, Hermanowicz NS. *Int J Neurosci*. 2008.
32. An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential. Patterson JV, Sandman CA, Ring A, Jin Y, Bunney WE Jr. *Bipolar Disord*.1: 596-609, 2009.
33. A Preliminary Study on rTMS Treatment in Childhood Autism. Dang WM, Jin Y, Huang YQ, Liu J. et al. *Journal of Chinese Neuropsychiatry*. 35(8):505-506, 2009
34. Magnetic neuro-EEG synchronization therapy for nonresponders to medication for depression: A multi-center randomized, double-blind, sham-controlled trial. Tang N, Jin Y, Zhan S, Huang Y. 24: 435-439, 2010
35. α EEG Guided MTS in Schizophrenia. Jin Y, Yueqin Y, Thai TM, Liu Z, Xu W, He H. et al. *J Brain Stim*. 2011

36. Impact of playing American professional football on long-term brain function. Amen DG, Newberg A, Thatcher R, Jin Y, Wu J, Keator D, Willeumier K. *J Neuropsychiatry Clin Neurosci*. 23:98-106, 2011.
37. Therapeutic application of transcranial magnetic stimulation in autism spectrum disorders. Jin Y, Ring A, Thai T, and Huang Y. *AUTISM SCIENCE DIGEST: THE JOURNAL OF AUTISMONE*. 2011(3) : 74-79.
38. rTMS Treatment for Autism. Jin Y. *Asia Health Care*. 2011: 22-25.
39. The Relationship Between Brain Oscillatory Activity and Therapeutic Effectiveness of Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder. Leuchter A., Cook I., Phillips W., Jin Y. *Frontiers in Human Neuroscience* 2013: 1-12
40. Effect of Active Paced Cardiolocomotor Synchronization during Running: A Preliminary Study. Phillips W. and Jin Y. *J Sports Science and Medicine*. 2013: 381-387
41. Gamified Dual-Task Training for Individuals with Parkinson Disease: An Exploratory Study on Feasibility, Safety, and Efficacy. Chua LK, Chung YC, Bellard D, Swan L, Gobrelal N, Romano A, Glatt R, Bonaguidi M, Lee DJ, Jin Y, Liu C, and Fisher BE. *IJERPH*. 18:12384, 2021